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Mutations in HNF1B are responsible for a dominantly inherited
disease with renal and nonrenal consequences, including
maturity-onset diabetes of the young (MODY) type 5.
While HNF1B nephropathy is typically responsible for bilateral
renal cystic hypodysplasia in childhood, the adult phenotype is
poorly described. To help define this we evaluated the clinical
presentation, imaging findings, genetic changes, and disease
progression in 27 adults from 20 families with HNF1B
nephropathy. Whole-gene deletion was found in 11 families,
point mutations in 9, and de novo mutations in half of
the kindred tested. Renal involvement was extremely
heterogeneous, with a tubulointerstitial profile at presentation
and slowly progressive renal decline throughout adulthood
as hallmarks of the disease. In 24 patients tested, there were
cysts (p5 per kidney) in 15, a solitary kidney in 5, hypokalemia
in 11, and hypomagnesemia in 10 of 16 tested, all as
characteristics pointing to HNF1B disease. Two patients
presented with renal Fanconi syndrome and, overall,
4 progressed to end-stage renal failure. Extrarenal phenotypes
consisted of diabetes mellitus in 13 of the 27 patients,
including 11 with MODY, abnormal liver tests in 8 of 21, diverse
genital tract abnormalities in 5 of 13 females, and infertility in
2 of 14 males. Thus, our findings provide data that are useful
for recognition and diagnosis of HNF1B disease in adulthood
and might help in renal management and genetic counseling.
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HNF1B is a developmental gene coding for hepatocyte
nuclear factor 1 homeobox B, a transcription factor first
isolated in human hepatocytes.1 During murine development
and in adult mice, Hnf1b has tissue-specific expression in
polarized epithelia of the pancreas, liver, renal, and genital
tracts.2–4 A direct hierarchy of Hnf1b upon the expression of
renal cystic (Pkhd1, Pkd2, and Umod) and noncystic (Fxyd2)
genes is established in mouse. In humans, heterozygous
mutations of HNF1B are responsible for a dominantly
inherited disease with both renal and extrarenal phenotypes.5
Genetic changes consist of whole-gene deletion in B50% of
the patients, whereas point mutations are detected in the
majority of the remaining cases.6–8 Extrarenal manifestations
include maturity-onset diabetes of the young type 5
(MODY5);9 exocrine pancreatic failure; fluctuating liver tests
abnormalities; and genital tract abnormalities.5,10
Renal involvement has emerged as the earliest and most
prevalent finding in HNF1B disease,6 with phenotypic
heterogeneity including renal malformations and tubular
transport abnormalities. Prenatally, the most frequent pre-
sentation consists of bilateral hyperechogenic kidneys with or
without cortical cysts,11 whereas bilateral renal hypodysplasia
with few or multiple cysts is more prevalent in early
childhood.12,13 Renal magnesium wasting affects up to 50%
of children.12
HNF1B nephropathy may present only in adulthood.
Diagnosis remains extremely challenging given that (1)
de novo mutations are encountered in up to 30–50% of
new cases;5,7,11 (2) in kindred with evidence for autosomal-
dominant inheritance, large intrafamilial variability of the
renal phenotype is striking;7,8 and (3) demonstration of
phenocopies can be seen in some families.5 In addition, all
previous reports share serious limitations, being mostly
devoted to syndromic presentations in isolated individuals
or kindred,3,12,14–21 and the description of novel muta-
tions,3,12,14–21 or biased by prespecifying MODY5 phenotype
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as one criterion for inclusion.5,6 Therefore, a comprehensive
assessment of phenotype and long-term outcomes of HNF1B
nephropathy in adulthood is still lacking.
The current study was profiled to delineate the clinical
presentation, molecular basis, and outcome in 27 adult
patients with HNF1B nephropathy. Particular emphasis
was placed upon detecting differences in the presentation
and outcome in families with point mutation vs whole-gene
deletion.
RESULTS
Within 20 families, we identified 35 individuals with HNF1B
disease: 27 adults (14 males and 13 females) and 8 additional
offspring lesser than 16 years of age (2 fetuses and 6 children;
see Figure 1). In the adult group, genetic testing was made at
the time of family screening in 11 individuals, including
9 (33%) for whom the proband was an affected child or fetus.
In the 16 adult probands, half the presenting manifestations
occurred in childhood whereas half occurred in adult life.
Mutation analyses: HNF1B alterations
All 27 individuals harbored a heterozygous molecular
alteration of HNF1B (see Table 1 and Supplementary Table
S1 online and Figure 1). Quantitative multiplex PCR of short
fragments detected whole-gene deletion in 11/20 families
(55%; 16 individuals). Direct DNA sequencing revealed
point mutations in 9/20 families (45%; 11 individuals),
including 7 previously reported in unrelated families (c.345-
1G4A, c.544þ 1_544þ 4del4, p.Val61Gly, p.Arg165His,
p.Gln253Pro, p.Arg276Gly, and p.Arg295Cys),6,7,11 and two
novel missense mutations (p.Leu286Val and p.Asn289Asp).
None of the novel nucleotide variants could be detected in
100 control individuals.
Genotyping of apparently unaffected parents of adult
probands was performed in 14 of the 20 families. De novo
mutation was found in 7/14 (50%), including three kindred
with whole-gene deletion (43%) and four with a point
mutation (57%). Among the latter, we could demonstrate
one patient with novel missense mutation (family 17) and
one patient with splice site mutation (family 14).
Clinical phenotype
Data were collected at a median age of 35 years (16–74). The
male-to-female ratio was 1.1:1. Four patients were symptom
free when screening was performed between 21 and 46 years
of age. Among the remaining 23 patients, the first
manifestation of HNF1B disease was kidney involvement in
14 (61%), diabetes mellitus in 2 (9%), genital tract
malformations in 4 (18%), and liver tests abnormalities in
3 (12%; Tables 1 and 2, and Figure 1).
Kidney involvement
Among the 14 patients who presented with renal disease, the
first manifestation was noticed prenatally in 6, during
childhood in 4, and during adulthood in 4 (aged 29–63
years; see Table 3 for details regarding antenatal and
childhood presentation). In the latter, renal presentation
consisted of chronic renal failure with small kidneys and few
(n¼ 2), multiple (n¼ 1), or no cysts (n¼ 1).
The 27 patients enrolled in the cohort were followed for a
median of 5.5 years (1–29) and had a median age of 35 years
(16–74) at last follow-up. Urinalysis was usually bland: none
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Figure 1 |Pedigrees of 20 families with HNF1B mutation. Filled quarters denote organ involvement. #These individuals had no molecular
analysis, but their genotype was deduced from that of affected siblings (see text for details).
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of the patients had microhematuria, 20 had no proteinuria,
and 7 had a low-grade proteinuria (o1 g/l). Polyuria was not
clinically evident. Only two individuals (7%) were hyperten-
sive, including one (F13.1) with reflux nephropathy. On
follow-up, hypokalemia or hypomagnesemia was detected in
15 patients (62%). Serum potassium levels were sponta-
neously o3.5mmol/l in 11 of 24 tested individuals (46%).
Hypokalemia resulted from renal loss (urinary Kþ concen-
tration 430mmol/l) and persisted despite worsening renal
decline. Ten individuals with chronic kidney disease stage 3–5
had serum potassium levels o3.5mmol/l, including one
patient (F6.3) with a serum potassium concentration of
2.6mmol/l at the start of dialysis. Serum magnesium levels
were o0.75mmol/l in 10 out of the 16 individuals tested
(62%). Magnesium depletion also resulted from renal
wasting (fractional urinary magnesium excretion (FEMg:
7–22%, No0.5%)). Oral supplementation with Mg2þ or
Kþ did not restore either serum magnesium or potassium
levels. The prevalence of hypokalemia and hypomagnesemia
was roughly similar in patients with gene deletion and point
mutation (Table 4). All but two patients with hypokalemia
also had concurrent hypomagnesemia. In contrast, only five
out of nine patients with hypomagnesemia had hypokalemia.
Last, five out of eight individuals had low urinary calcium
excretion.
Two unusual patients (F16.1 and F20.1) presented with
generalized defects of proximal and distal tubular function,
including tubular proteinuria, generalized aminoaciduria,
renal glucosuria, phosphaturia, hypomagnesemia, hypokale-
mia, and incomplete renal tubular acidosis associated with
hypercalciuria and recurrent nephrolithiasis. In both, genetic
testing ruled out a concomitant mutation or deletion in
HNF1A, the gene responsible for MODY3.
Renal imaging was available in 24 of the 27 patients
(89%). At last follow-up, extreme heterogeneity was found,
falling grossly into four categories with possible overlap: (1)
normal kidneys, that is, two normally sized kidneys without
detectable cysts (3/24, (12%)); (2) a solitary kidney seen in
5/24 individuals (21%); (3) renal cysts in 15/24 individuals
(62%), including 11 with few (that is, p5) cortical or
medullary cysts per kidney (In most cases, cysts developed
within the cortex, sparing the kidney outline. There was no
correlation seen between the degree of renal cystic involve-
ment and the severity of renal failure (data not shown). Of
note, 9 patients (38%) had no renal cysts between 16 and 48
years of age.); and (4) a wide range of kidney and urinary
tract abnormalities, including nephrocalcinosis, kidney
stones, hydronephrosis or hydroureter, and vesicoureteric
reflux (16%). One patient (F11.1) developed a renal tumor at
age 20 years. She declined surgical treatment.
Table 1 | Renal phenotype at last follow-up in 27 adult patients with HNF1B mutation
Family.
patient Gender Age eGFR K+ Mg++ MgUE Ca++ CaUE Renal imaging Mutation
F1.1 M 40 52 3.7 0.6 7% 2.41 0.3% Solitary RK, few cysts and pyelic dilatation Deletion
F2.1 F 38 100 4 — — — — Normal Deletion
F3.1 M 19 — — — — — — — Deletion
F3.2 F 24 15 3.2 0.66 2.4 Mimicking ADPKD Deletion
F3.3 F 23 28 3.3 0.67 2.35 Mimicking ADPKD Deletion
F4.1 F 21 23 4 — — 2.52 Solitary LK, few cysts (R-MCDK involution) Deletion
F5.1 F — — — — — — — — Deletion
F5.2 M 48 45 3.8 — — 2.4 Hypoplastic RK Deletion
F5.3 F 40 52 3 — — 2.33 — Normal Deletion
F6.1 M 55 64 3.1 0.52 14% 2.23 1.8% Few cysts c.544+1_544+4del4
F6.3 M 31 ESRD 2.6 — — 2.36 — Bilateral hypoplasia and VUR c.544+1_544+4del4
F6.4 M 29 65 — — — — — Solitary LK, few cysts c.544+1_544+4del4
F7.1 M 53 26 3.9 0.66 — 2.48 4% Few cysts Deletion
F8.1 F 57 45 3.4 — — 2.49 Bilateral hypoplasia, few cysts Deletion
F9.1 M 63 29 4 1 — — Many bilateral cysts Deletion
F10.1 M 74 47 4.2 0.72* 8% 2.86a 1% Few cysts, nephrocalcinosis p.Val61Gly
F11.1 F 22 55 4 0.48 7% 2.4 0.4% Few cysts p.Gln253Pro
F12.1 M 27 33 3.8 — — 2.4 Bilateral VUR and pyelic dilatation Deletion
F13.1 F 46 94 3.9 1 — 2.2 — Deletion
F13.2 F 48 ESRD 4 1 — 2.4 Hypoplastic RK with few cysts Deletion
F14.1 M 16 23 3.4 0.7 22% 2.43 2.3% Solitary RK (L-MCDK involution) c.345-1G4A
F15.1 M 17 45 3.4 0.78 5% 2,46 0.2% Bilateral hypoplasia, few cysts Deletion
F16.1 F 38 ESRD 3.4 0.65 — 2.4 — Bilateral nephrolithiasis and pyelic dilatation p.Arg276Gly
F17.1 F 21 38 3.4 0.9 4% 2.25 Solitary LK (R-MCDK involution) p.Asn289Asp
F18.1 M 18 ESRD 4 1 — 2.3 — Bilateral Nx (age 7, bilateral MCDK) p.Arg165His
F19.1 F 38 68 3.9 — — 2.13 0.2% Bilateral hypoplasia, few cysts, lithiasis p.Arg295Cys
F20.1 M 32 23 3 — — 1.9 — Nephrocalcinosis, nephrolithiasis p.Leu286Val
Abbreviations: ADPKD, autosomal-dominant polycystic kidney disease; Ca2+, serum calcium level (mmol/l); CaUE, calcium urinary excretion (%; (U/P)[Ca]/(U/P)[creatinine];
N 41%); eGFR, estimated glomerular filtration rate (ml/min per 1.73m2; simplified Modification of Diet in Renal Disease (MDRD) formula); ESRD, end-stage renal disease;
F, female; K+, serum potassium level (mmol/l); L, left; LK, left kidney; M, male; MCDK, multicystic and dysplastic kidney; Mg2+, serum magnesium level (mmol/l);
MgUE, magnesium urinary excretion (%; (U/P)[Mg]/(U/P)[creatinine]; N o2%); Nx, nephrectomy; R, right; RK, right kidney; VUR, vesicoureteral reflux.
*Mg2+ oral supplementation.
aPrimary hyperparathyroidism was evidenced in patient F10.1.
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Kidney size was not available in two individuals, was
normal in 13 (61%), decreased in 7 (30%; unilaterally in 2
and bilaterally in 5), and was massively enlarged in two
homozygotic twins (9%) who harbored a renal phenotype
mimicking autosomal-dominant polycystic kidney disease
Table 2 | Individual extrarenal phenotype in 27 adult patients with HNF1B mutation
Family.
patient
DM (age at
diagnosis)
Initial
presentation
Insulin
therapy
at last FU
Pancreas
imaging
Liver test
abnormalities
Genital tract
abnormalities Additional findings
F1.1 No — — Tail
hypoplasia
No CBAVD, cryptorchidy —
F2.1 No — — Normal Yes Bicornual uterus —
F3.1 MODY (19) — — — — — —
F3.2 MODY (21) Slow Yes Normal No No —
F3.3 MODY (21) Slow No Normal No No —
F4.1 No — — Normal No No —
F5.1 No — — — No Bicornual uterus —
F5.2 MODY (31) Slow Yes — Yes — Inguinal hernia
F5.3 Gestational — — — — Bicornual uterus —
F6.1 No — — — — No —
F6.3 No — — — — — Mental retardation, growth
delay
F6.4 No — — — — — —
F7.1 MODY (41) Slow Yes — Yes — —
F8.1 No — — — — — —
F9.1 MODY (—) Slow No — Yes — —
F10.1 MODY (41) Slow Yes — No — —
F11.1 No — — Normal No No, pre-eclampsia Renal tumor (age 20)
F12.1 MODY (23) Ketoacidosis Yes Normal Yes — —
F13.1 MODY (43) Slow No — No No, pre-eclampsia —
F13.2 MODY (33) Slow Yes Normal Yes Uterus absence,
vaginal hypoplasia
Mental retardation, cervical
cancer (age 19)
F14.1 No — — — No — —
F15.1 No — — Normal No — —
F16.1 Post-RT (37) Early Yes Normal Yes — —
F17.1 No — — Tail
hypoplasia
No No —
F18.1 Post-RT (8) Early Yes Normal No Bilateral epidydimes
and vas deferens cysts
Mental retardation, cortical and
cerebellum hypoplasia, epilepsy
F19.1 No — — Tail
hypoplasia
No Septate uterus,
ovarian cyst
—
F20.1 MODY (23) Ketoacidosis Yes Calcifications
and tail
hypoplasia
Yes — Epilepsy
Abbreviations: CBAVD, congenital bilateral absence of vas deferens; DM, diabetes mellitus; FU, follow-up; MODY, Maturity-Onset Diabetes of the Young; RT, renal transplantation.
Table 3 | Renal phenotype at presentation and at last
follow-up in 10 adult patients with first renal
manifestation during antenatal period (n=6) or in
childhood (n=4)
Presentation
Last follow-up
(adulthood)
Antenatal
Bilateral cystic kidneys (n=2) Massively enlarged cystic kidneys
(n=2)
Unilateral MCDK (n=3) MCDK involution (n=3) and few
cysts (n=1)
Bilateral hypoplastic and
microcystic kidneys (n=1)
Bilateral nephrectomy at age 6
(n=1)
Childhood
Bilateral pyeloureteric
junction syndrome (n=1)
Surgery at age 1, bilateral ureteric
and caliceal dilatation at last follow-
up (n=1)
Bilateral hypoplastic kidneys
(n=1)
Bilateral hypoplastic kidneys with
few cysts (n=1)
Cystic kidneys (n=1) Cystic kidneys (n=1)
Right nephrectomy of
unknown cause (n=1)
Few cysts (n=1)
Abbreviation: MCDK, multicystic and dysplastic kidney.
Table 4 | eGFR assessment and frequency of
hypomagnesemia and hypokalemia in HNF1B patients
according to genetic change
Deletion
Point
mutation P-value
N 16 11
Age at latest follow-up
(years)
38.9±14.6
(17–63)
36.9±18.6
(16–74)
NS
eGFR (sMDRD, ml/min
per 1.73m2)
36.6±22.4
(0–100)
41.1±29.6
(0–88)
NS
Low serum magnesium
(n/n examined)
4/8 (50%) 6/8 (75%) NS
Low serum potassium
(n/n examined)
5/14 (36%) 5/10 (50%) NS
Abbreviations: eGFR, estimated glomerular filtration rate; NS, not significant; sMDRD,
simplified Modification of Diet in Renal Disease.
Po0.05 was considered as significant (Mann–Whitney test).
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(patients F3.2 and F3.3; for details, see Faguer et al.17).
Figure 2 shows the kidney length at last follow-up according
to age. In the six cystic individuals who underwent sequential
imaging, none showed a progressive increase in the number
of cysts over time.
At last evaluation, estimated glomerular filtration rate
(eGFR) was available in 25 of the 27 individuals and ranged
from 0 to 100ml/min per 1.73m2 (median 38). According to
chronic kidney disease classification, two patients were
ranked stage 1, four stage 2, nine stage 3 (including one in
her eighth decade), and six stage 4. Four patients (15%)
progressed to end-stage renal failure at 7, 22, 29, and 31 years
of age, respectively (Figure 3). In the 17 individuals not in
end-stage renal failure for whom sequential assessment of
eGFR was available over a median follow-up period of 5.5
years (1–16), the median yearly decline of eGFR was slow
(2.45ml/min/year), with individual changes ranging
between 0 and 19ml/min/year. Three individuals had
unexplained acute renal deterioration. No renal biopsy was
performed in this series. Renal prognosis was not predicted
by genetic changes (large deletion vs point mutation; see
Figure 3 and Table 3). Renal transplantation was performed
in three patients. By the end of the study, two grafts were
still functional.
Gross kidney abnormalities and the course of renal disease
within families were either homogeneous (family F3), or
moderately (family f5) and even extremely heterogeneous
(families F6 and F13).
Extrarenal phenotype
With the exception of diabetes mellitus, extrarenal involve-
ment related to HNF1B disease was not systematically
searched for (Table 2 and Supplementary Table S2 online).
Diabetes mellitus was diagnosed in 13/27 patients (48%): 11
presented with MODY and 2 with ketoacidosis. On follow-
up, 9 patients required insulin therapy. None developed
diabetic retinopathy or neuropathy. At last follow-up, the
median age of MODY5 and nondiabetic individuals was
similar (37 (18–74) vs 31 (16–57) years, P¼ 0.31).
Additional extrarenal findings consisted of pancreas
hypoplasia (33%); liver test abnormalities (40%): serum
titers of transaminases, alkaline phosphatase, and g-glutamyl
transferase fluctuated up to 10 times the upper limits of
normal; genital tract malformation (5 of 12 (45%) tested
females and 2 males); and mild-to-moderate mental retarda-
tion without concomitant hypomagnesemia (11%; see Table 2
and Supplementary Table S2 online, and Figure 4 for details).
DISCUSSION
Genetics
This study demonstrates the wide heterogeneity of both
phenotype and genotype among adult patients with kidney
involvement related to molecular alteration in HNF1B.
The study was conducted in 27 middle-aged adults from
20 unrelated families. Large genomic rearrangement proved
to be the most frequent genetic alteration (seen in 55% of all
families). In HNF1B patients, whole-gene deletion encom-
passes a genomic region of at least 1.2 megabases,6 and
accounts for 36% of the genetic mutations in MODY5
adults,6 and up to 83% in fetuses who present with renal
abnormalities.11 In the 11 families with whole-gene deletion,
assignment of pathogenesis was straightforward, as well as in
the four additional families with point mutations previously
reported. In contrast, determining pathogenicity remains
challenging in the absence of a functional assay for the novel
point mutations identified in two families. We considered
these variants as likely pathogenic given that (1) all mutations
were localized in the DNA-binding domain where a known
hot spot has been demonstrated;7 (2) they affect highly
conserved amino-acid residues between distant species
and bioinformatics tools (PolyPhen: http://genetics.bwh.
harvard.edu/pph/) predicted pathology; (3) they occurred
de novo (family 17); and (4) they were not present in 200
chromosomes from white controls.
De novo mutation was a frequent finding, reaching 50%
among the 14 families available for testing. This figure is
close to the 53–58% rates found in two pediatric cohorts with
renal abnormalities.11,22 This finding has one ominous
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consequence: in patients with a suggestive phenotype, the
lack of family history should not prevent consideration
of HNF1B disease as a possibility.
Renal phenotype
Previously, the description of HNF1B nephropathy was
confined to sporadic cases,3,20,21 cross-sectional studies in
children,3,7,9,13,20–22 or cohorts of MODY5 adult patients with
limited follow-up.5,6 This study, which represents the largest
series of adults with HNF1B disease, highlights the hetero-
geneity of the renal involvement and provides unique
landmarks to prompt early recognition. For the first time,
we establish that the renal phenotype in adults with HNF1B
disease is clearly one of chronic tubulointerstitial nephritis.
Characteristic findings of bland urinalysis in 74% of patients,
the universal absence of hematuria and urinary protein
excretion o1 g/l in all tested patients, the low prevalence of
hypertension (7%), and slowly progressive kidney failure
(with a median yearly eGFR decline of 2.45ml/min per
1.73m2) are the hallmarks of this disease. In adult patients
with HNF1B mutation, renal biopsy may show nonspecific
interstitial fibrosis and, to a lesser extent, enlarged glomeruli
or oligomeganephronia.5 Polyuria, characteristic of nephro-
nophthisis,23 was not observed in our adult patients with
HNF1B mutation. Furthermore, in contrast with previous
findings,13,24 gouty attack was not a presenting manifestation
in this cohort.
One of the strengths of this study is the systematic
description of kidney imaging in 24 adult HNF1B mutation
carriers. We observed a puzzling heterogeneity of gross
kidney structural anomalies, evading easy classification.
The most suggestive finding was a cystic phenotype, observed
in 62% of this adult population. This figure is in keeping
with previous studies in adults with MODY5,5,6 where
macroscopic cysts were a frequent (29/36, or 81%) but not a
universal finding. Of note, most cystic patients harboredp5
cortical cysts in each kidney, and with the exception of
homozygotic twins,17 the course of renal pathology was not
characterized by a progressive increase in the number of cysts
or in kidney size, a distinctive finding as compared with
polycystic kidney disease, with either recessive or dominant
inheritance. Another intriguing finding is the asymmetry
of urinary tract involvement, with 21% of the patients
presenting with a solitary kidney in adulthood. A single
kidney in HNF1B patients may result from a progressive
atrophy of a multicystic dysplastic or hypoplastic kidney.11
However, a previous study found that HNF1B mutation
accounts for only 8% of unilateral solitary kidney.22 Lastly,
subtle changes of the urinary tract consisting of clubbing or
tiny diverticulae of calices and ureteric strictures were not
found in this study, in contrast with our earlier experience
with MODY5 patients.5,12 These changes are best detected by
intravenous pyelography or magnetic resonance urography
and were possibly overlooked.
In this adult HNF1B cohort, we identified hypomagnese-
mia in 62% and hypokalemia in 46% of the tested patients.
Both were related to inappropriate renal loss. The prevalence
of hypomagnesemia is in line with the 44% rate recently
reported in HNF1B children.12 The kidney is involved in the
fine-tuning of magnesium homeostasis; thus, HNF1B
nephropathy should now be considered among the eight
monogenic forms of renal hypomagnesemia identified at the
molecular level.25 The mechanism leading to hypomagnese-
mia is ascribed to direct control of FXYD2 gene expression
by HNF1B.12 Mutations of FXYD2 are also responsible for
autosomal-dominant renal hypomagnesemia with hypocal-
ciuria.25 However, four patients in this study had hypomag-
nesemia without concomitant hypocalciuria.
*
Figure 4 | The spectrum of abdominal imaging findings in HNF1B patients. (a, b) Abdominal computed tomography (CT) scan: bilateral
small kidneys with nephrolithiasis (a, patient F19.1); solitary left kidney with few cortical cysts (b, patient F4.1). (c, d) Abdominal magnetic
resonance imaging (MRI): left solitary kidney without cyst (c, patient F17.1); multicystic kidneys mimicking autosomal-dominant polycystic
kidney disease (d, patient F3.2). (e, f) Abdominal CT scan: hypoplasia of pancreas tail (e, patient F1.1); calcification of pancreas head
(f, patient F20.1). (g) Abdominal MRI (patient F20.1, chronic cholestasis): normal biliary tree. (h) Pelvic CT scan: septate uterus
(star, patient F19.1).
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A key finding in this report is that nearly half of our
patients presented with hypokalemia (o3.5mmol/l), despite
the fact that the majority of cases were chronic kidney disease
stage 3–5. The pathophysiology of hypokalemia in HNF1B
patients is unknown. Hypokalemia was not previously
mentioned in HNF1B children with hypomagnesemia, nor
in previous pediatric series.11,22 Whether renal potassium
wasting in HNF1B adult patients results from a specific
transcriptional HNF1B effect or from long-standing hypo-
magnesemia has not yet been established. However, refrac-
tory hypokalemia and potassium depletion are frequently
associated with magnesium deficiency regardless of its
mechanism, and may persist until the magnesium deficiency
is restored. Recently, Yang et al.26pointed out that magnesium
depletion modulates renal outer medullary potassium
channel-mediated potassium secretion. Low serum magne-
sium and potassium may also be encountered in patients
with Gitelman syndrome. In the latter, metabolic alkalosis
and salt-losing tubulopathy are part of the metabolic changes,
but were not observed in HNF1B patients. Furthermore, the
genes responsible for Gitelman syndrome (that is, SLC12A3
and CLCNKB) are not predicted to be target gene
of HNF1B.12 Future studies using a large-scale approach
(that is, chromatin immunoprecipitation followed by DNA
microarray or high-throughput sequencing) should test
whether genes involved in the molecular machinery of renal
potassium handling are involved in the HNF1B transcrip-
tional network.
Surprisingly, two patients exhibited both distal tubular
defects and a generalized dysfunction of proximal tubular
function resulting in renal Fanconi syndrome. Renal Fanconi
syndrome is a well-established complication of HNF1A
mutations in both mice and humans.27,28 In the latter,
pancreatic involvement is responsible for MODY3. In our
patients, digenism involving both HNF1A and HNF1B was
ruled out. Whether HNF1B plays a direct role in the adult
human proximal tubule is currently unknown. In rodents,
Hnf1b binds DNA as a homodimer or heterodimer with the
related factor Hnf1a. Activity of either partner may
differentially affect the target genes.29 Should this occur in
humans, and if both patients carried a point mutation, a
dominant-negative effect of HNF1A/HNF1B heterodimers
could account for the phenotype. Alternatively, interacting
genes may participate in phenotypic heterogeneity.
Chronic renal failure was found in 92% of the patients at a
median age of 35 years. The severity of kidney failure was
related neither to genetic changes (deletion vs point
mutation) nor to MODY phenotype. A larger cohort should
be assessed to confirm these findings. In this cohort, no renal
biopsy was performed. Suggestive findings in HNF1B adults
with MODY5 may include oligomeganephronia, glomerular
cysts, or tubular dilatation.5 Although the age at end-stage
renal disease remains largely unpredictable, the slope of renal
decline exhibited two main characteristics. First, the median
decline was slow (2.45ml/min/year). This figure is nearly
identical to our previous experience in 8 patients with
MODY5 (1.1ml/min).5 Second, HNF1B patients may
experience acute unexplained worsening of renal failure.
Whether a defective renal tubular repair following acute
kidney injury is involved in human HNF1B-mutated kidney
cells should be assessed. Indeed, mice with renal-specific
HNF1B inactivation develop tubular cysts and renal failure
within 3 weeks following acute kidney injury.30 Altogether,
the prevalence rate of end-stage renal disease in HNF1B adult
patients was 3% among 28 MODY5 adults,6 and 15% in this
series.
HNF1B patients are good candidates for kidney trans-
plantation. However, they are at risk of developing early
new-onset diabetes post transplantation, as exemplified by
two cases in this series. In nondiabetic individuals, a tailored
immunosuppressive regimen should optimally avoid tacro-
limus and reduce corticosteroid dosage to minimize the risk
of developing diabetes mellitus.31 In diabetic HNF1B patients
with end-stage renal failure, simultaneous pancreatic and
kidney transplantation should be considered.
Last, one female patient developed a renal solid tumor at
age 20 years. The patient has so far declined surgery.
Intriguingly, the occurrence of a chromophobe renal cancer
has been previously described in two HNF1B patients at
34 and 54 years of age and regular screening was advocated.32
In this cohort, no renal cancer was detected, even in renal
graft recipients.
Extrarenal phenotype
Extrarenal manifestations are efficient tools for diagnosing
many renal disorders, including inherited conditions. Given
the wide range of renal phenotypes in HNF1B disease,
recognition of extrarenal signs is critical. Although no
systematic assessment was performed in this retrospective
study, extrarenal involvement deserves four comments. First,
liver test abnormalities were identified in 40% of cases as
compared with 85% in adult patients with the MODY5
phenotype.5,6,10 Whether the hepatic course will remain
indolent in the long term is unknown. Indeed, liver-specific
Hnf1b deletion in mice results in severe jaundice, paucity of
intrahepatic bile ducts, and lack of interlobular arteries.33
Second, both exocrine and endocrine pancreatic function
can be affected. The rate of pancreatic atrophy in a previous
study of adults with MODY5 was 83%.5 In this series, 30%
were found to have pancreatic atrophy, while diabetes
mellitus was found in only 48% of the patients. Thus,
diabetes mellitus should no longer be regarded as a
prerequisite to diagnose HNF1B disease, even in adulthood.
The presentation of diabetes was not uniform. Two patients
came to attention because of diabetic ketoacidosis, while
11 presented with typical MODY. On follow-up, diabetes
mellitus had a slowly progressive course. By the last visit, 69%
of diabetic individuals required insulin but none developed
diabetic retinopathy or neuropathy, suggesting that HNF1B
patients may be protected against microvascular disease as
previously noted in MODY5 individuals.5,10 In keeping with
this hypothesis, diabetic glomerulopathy has not been
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observed in kidney specimens from MODY5 patients.5,10
Whether all HNF1B individuals will ultimately develop
diabetes mellitus is not yet known.
Third, we found a 42% rate of genital tract abnormalities
in HNF1B females, with bicornuate uterus emerging as the
most frequent manifestation. Bicornuate, rudimentary
uterus, single or absent ovaries, vaginal atrophy, and
absent genitourinary tracts have all been previously
reported.5,10,21,34 Recently, Oram et al.34 found an 18% rate
of HNF1B mutations in patients with both renal and uterine
malformations.
Finally, mild but obvious mental retardation was recog-
nized in three patients, including two with missense
mutations. Whole-gene HNF1B deletion or duplication
may be associated with autistic features35,36 or mental
retardation with epilepsy and focal cortical dysplasia.37,38
Whether neurological involvement is part of the spectrum
of HNF1B disease is not yet elucidated, as other causes of
cognitive impairment were not ruled out.
In summary, this unique series unveils a previously
undescribed aspect of renal involvement in adult patients
with HNF1B disease. Despite its shortcomings, data from this
study should improve prompt recognition of HNF1B disease
in adulthood and prove useful for renal management and
genetic counseling.
MATERIALS AND METHODS
Recruitment
Participants were recruited from four adult renal units in France
and Belgium (university hospitals in Toulouse, Clermont-Ferrand,
and Paris (Tenon Hospital) and Cliniques Universitaires Saint-Luc
in Brussels). Inclusion criteria included positive genetic testing for
HNF1B and ageX16 years. As no consensus has yet been reached on
when to test for HNF1B mutation, indications for testing during the
enrollment period included the presence of at least one of the
following four conditions: (1) renal disease with multisystem
involvement (diabetes with a MODY phenotype, pancreatic
hypoplasia, unexplained elevated liver enzymes, or genital tract
abnormalities); (2) renal disease of unknown origin but concomi-
tant findings suggestive of autosomal-dominant inheritance (X1
first-degree relative with unexplained renal disease); (3) unexplained
renal disease presenting with hypodysplasia and renal cysts; or (4)
family screening in first-degree relatives of HNF1B mutation
carriers.
Informed written consent was obtained from all subjects and
tested relatives, and the study was conducted in agreement with
the Declaration of Helsinki Principles. A total of 27 patients from
20 unrelated families with HNF1B mutations were identified. With
the exception of two individuals from family 3 who exhibited an
uncommon renal phenotype,17 none of the 27 adult patients
recruited for this study have been reported so far.
HNF1B genetic analysis
Genomic DNA was extracted from peripheral lymphocytes using
standard procedures. Genetic analysis first assessed HNF1B
(reference sequence NM_00458.2) rearrangement by quantitative
multiplex PCR of short fragments, followed by direct sequencing
of the 9 exons and exon–intron boundaries of the HNF1B gene,
including individuals without quantitative multiplex PCR of
short fragment abnormalities as recommended.6 Genetic testing
was conducted by three genetic laboratories in Paris, Brussels,
and Toulouse. Family relationships were not tested in this study.
For this report, we excluded three families who presented with an
HNF1B-like phenotype but had missense nucleotide variants in the
HNF1B gene (p.Gly76Cys, n¼ 2; p.Val25Leu, n¼ 1) currently
considered to be polymorphisms unlikely to cause HNF1B disease12
(C Bellanne´-Chantelot, personal communication).
Clinical evaluation
Renal and extrarenal involvement in the probands was recorded
using a standardized assessment of hospital records. Hypertension
was defined by blood pressure 4140/90mmHg or the use of
antihypertensive medication. Hematuria was assessed by urinary
dipstick analysis. eGFR was estimated using the simplified
Modification of Diet in Renal Disease (MDRD) formula.39 Renal
failure was defined by eGFRo60ml/min per 1.73m2. In patients on
renal replacement therapy, eGFR was arbitrarily set at 0. The rate of
decline of renal function was analyzed in a subgroup of patients
who hadX2 eGFR measurements available more than 1 year apart,
expressed as ml/min per 1.73m2 per year. Hypokalemia and
hypomagnesemia were defined by serum potassium levels
o3.5mmol/l and serum magnesium levels o0.75mmol/l, respec-
tively. No proband was treated with any medication that could affect
serum levels of potassium or magnesium. With the exception of
presenting manifestation, gouty attack and uric acid values were not
taken into consideration. Imaging studies of the kidney consisting of
ultrasonography, computed tomography, or magnetic resonance
imaging were reviewed. For the sake of clarity, the latest imaging test
was considered in this report. However, consecutive imaging
assessments provided sequential data on kidney morphology in six
individuals. Renal imaging was categorized according to cystic
involvement (0,o5, or X5 cysts/kidney) and renal length (increased
(42 s.d. for age), normal, or small (o2 s.d. for age)). Diabetes was
diagnosed on the basis of documented treatment with insulin and/or
oral hypoglycemic agents, or biochemical evidence of diabetes in
accordance with the World Health Organization guidelines. To avoid
misclassification related to phenocopies in relatives who were not
available for genetic testing, two at-risk relatives presenting with
diabetes above 40 years of age were considered noncarrier individuals
(for details, see Figure 1, families F5, individuals specified with gray
square). Genital tract abnormalities were assessed using magnetic
resonance imaging or ultrasonography.
Family assessment
All probands were interviewed regarding the presence of renal
disease or diabetes in at-risk relatives by the referring clinician.
Genetic screening and minimal clinical testing (fasting plasma
glucose and serum creatinine, and kidney ultrasonography) were
offered to all first-degree relatives regardless of their clinical status.
Statistical analysis
Characteristics of the study cohort are expressed using descriptive
statistics as median; minimum and maximum; and frequencies (%)
for discrete measures. Continuous variables were compared using
the Mann–Whitney test. Statistical significance was accepted as
Po0.05.
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